Multimorbidity, which is the coexistence of multiple chronic diseases in the same person, is becoming increasingly common in older adults. Advances in modern medicine mean that many conditions that were once fatal, such as stroke or heart disease, are now chronic and manageable. This is good news in terms of survival, but it has created a new challenge. Older adults often carry multiple chronic diseases at the same time. Understanding why some people develop multiple conditions while others remain relatively healthy is crucial for improving care, preventing disease progression, and enhancing quality of life.
A groundbreaking study published in Nature Medicine in January 2026 provides fascinating insights into the biological mechanisms underlying multimorbidity. By examining 54 blood biomarkers in more than 2,200 older adults over 15 years, researchers identified shared and disease-pattern-specific biological signatures. These findings could explain why some individuals accumulate chronic diseases faster than others.
Multimorbidity is not just having two or more diseases. It is a complex phenomenon with profound consequences. Studies suggest that up to 90 percent of people over the age of 60 experience multimorbidity. For some, it has a minor impact on daily life. For others, it contributes to frailty, disability, cognitive decline, and early mortality.
Traditional medicine often treats diseases in isolation. A patient with diabetes, hypertension, and chronic kidney disease might see three different specialists, each focused on a single organ or system. Multimorbidity is more than the sum of its parts because diseases can interact, worsen one another, and accelerate overall health decline. Understanding the underlying biology could allow healthcare providers to intervene earlier and more effectively.
Researchers analyzed data from the Swedish National Study on Aging and Care in Kungsholmen (SNAC-K), which included 2,247 individuals aged 60 and above. Participants were followed for 15 years, providing a rich longitudinal dataset. The team measured 54 blood-based biomarkers that reflect a wide range of biological processes:
The researchers examined three complementary measures of multimorbidity. The first measure was the total disease count at baseline, which counted how many chronic diseases a participant had at the start. The second measure was multimorbidity patterns, which are groups of diseases that tend to occur together. These patterns were identified using statistical modeling called latent class analysis. The third measure was the rate of disease accumulation, which tracked how quickly participants developed new chronic conditions over the 15-year follow-up.
By linking biomarkers to these measures, the researchers aimed to identify both shared biological mechanisms affecting multiple types of multimorbidity and pattern-specific processes influencing certain disease clusters.
One of the most interesting aspects of the study was the identification of five distinct multimorbidity patterns.
This classification is important because it moves beyond simply counting diseases. It captures the patterns of co-occurrence, which may reflect shared underlying biology.
The study revealed that certain biomarkers were consistently associated with multimorbidity, regardless of disease pattern or number of conditions. These shared biomarkers reflect metabolic, stress, and kidney pathways, suggesting that fundamental biological processes underlie the development of multiple diseases.
The five key shared biomarkers were:
In addition, gamma-glutamyl transferase (GGT), a liver enzyme reflecting metabolic stress, predicted faster accumulation of chronic diseases over time. Albumin, a marker of nutritional status and overall health, was inversely associated, suggesting that higher albumin levels may protect against rapid disease accumulation.
These findings point to metabolic dysregulation as a central driver of multimorbidity. GDF15, in particular, could serve as a potential biomarker for early identification of high-risk individuals.
While some biomarkers were shared across all disease types, others were pattern-specific, highlighting unique biological pathways for certain clusters.
Other markers, such as hemoglobin, were inversely associated with most patterns, emphasizing the role of nutrition and inflammation in multimorbidity.
To better understand the interplay between biomarkers, the researchers used principal component analysis to identify clusters of biomarkers that act together. This revealed primary and secondary subprofiles.
The primary subprofile included GDF15 and Cystatin C, highlighting stress responses and kidney and mitochondrial dysfunction. The secondary subprofile included metabolic markers such as insulin, HbA1c, and GGT, emphasizing energy dysregulation and systemic metabolic stress.
These subprofiles suggest that complex multimorbidity may emerge from a cycle of metabolic, inflammatory, and immunometabolic dysregulation. Metabolic stress triggers inflammation, which then worsens metabolic dysfunction, creating a self-reinforcing loop that accelerates disease accumulation.
The researchers validated their findings using data from 522 older adults in the Baltimore Longitudinal Study of Aging (BLSA). Despite differences in demographics and cohort size, the biomarker patterns and predictive models generalized well. The average prediction error for annual disease accumulation was less than 0.2 diseases per year, demonstrating strong external validity.
This study has important implications for understanding aging and chronic disease.
The accumulation of chronic diseases is tied to measurable biomarkers reflecting metabolism, stress response, and organ function. This opens the door to predictive diagnostics.
Markers such as GDF15, insulin, leptin, and HbA1c point to metabolism as a key driver of multimorbidity. Interventions targeting energy balance, insulin resistance, or mitochondrial health could potentially slow disease accumulation.
Identifying pattern-specific biomarkers allows for tailored preventive strategies. Individuals with the neuropsychiatric pattern could benefit from interventions supporting neuronal health, while those with cardiometabolic multimorbidity might benefit most from cardiovascular-focused interventions.
Lifestyle interventions, including exercise, nutrition, and weight management, remain critical. Additionally, certain medications used for metabolic diseases may offer broader benefits, protecting against cardiovascular, renal, musculoskeletal, and cognitive decline even in non-diabetic populations.
While the study is robust, several limitations should be noted.
Despite these limitations, the study provides a valuable roadmap for understanding the biological underpinnings of multimorbidity.
Multimorbidity is a defining challenge of modern aging populations, but it is not random. By examining a wide range of blood biomarkers over 15 years, researchers have uncovered shared and pattern-specific biological signatures. These findings highlight metabolic dysregulation as a central driver of disease accumulation.
Key shared biomarkers, including GDF15, HbA1c, insulin, leptin, and Cystatin C, provide a window into the processes linking aging, metabolic stress, and multimorbidity. Pattern-specific markers such as NfL and N-cadherin suggest opportunities for targeted interventions based on disease clusters.
This research supports a shift in focus from treating individual diseases to targeting fundamental aging processes. With further validation, blood biomarkers could become powerful tools for predicting, preventing, and slowing the accumulation of chronic diseases. These advances could improve healthspan and quality of life for older adults worldwide.
As populations age globally, studies like this pave the way for precision prevention and early interventions, ensuring that longevity is paired with health, vitality, and independence.
Ornago, A. M., Gregorio, C., Triolo, F., Moore, A. Z., Marengoni, A., Beridze, G., Grande, G., Bellelli, G., Dale, M., Fredolini, C., Ferrucci, L., Fratiglioni, L., Calderón-Larrañaga, A., & Vetrano, D. L. (2026). Shared and specific blood biomarkers for multimorbidity. Nature Medicine.
This blog post is intended for educational purposes only. It summarizes research findings from a scientific study and should not be used as medical advice. Always consult qualified healthcare professionals for diagnosis, treatment, and management of any medical conditions.
Most Accurate Healthcare AI designed for everything from admin workflows to clinical decision support.